401 related articles for article (PubMed ID: 33204365)
1. Explicating the Pivotal Pathogenic, Diagnostic, and Therapeutic Biomarker Potentials of Myeloid-Derived Suppressor Cells in Glioblastoma.
Richard SA
Dis Markers; 2020; 2020():8844313. PubMed ID: 33204365
[TBL] [Abstract][Full Text] [Related]
2. Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis.
Alban TJ; Alvarado AG; Sorensen MD; Bayik D; Volovetz J; Serbinowski E; Mulkearns-Hubert EE; Sinyuk M; Hale JS; Onzi GR; McGraw M; Huang P; Grabowski MM; Wathen CA; Ahluwalia MS; Radivoyevitch T; Kornblum HI; Kristensen BW; Vogelbaum MA; Lathia JD
JCI Insight; 2018 Nov; 3(21):. PubMed ID: 30385717
[TBL] [Abstract][Full Text] [Related]
3. Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion.
Otvos B; Silver DJ; Mulkearns-Hubert EE; Alvarado AG; Turaga SM; Sorensen MD; Rayman P; Flavahan WA; Hale JS; Stoltz K; Sinyuk M; Wu Q; Jarrar A; Kim SH; Fox PL; Nakano I; Rich JN; Ransohoff RM; Finke J; Kristensen BW; Vogelbaum MA; Lathia JD
Stem Cells; 2016 Aug; 34(8):2026-39. PubMed ID: 27145382
[TBL] [Abstract][Full Text] [Related]
4. Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives.
Lin H; Liu C; Hu A; Zhang D; Yang H; Mao Y
J Hematol Oncol; 2024 May; 17(1):31. PubMed ID: 38720342
[TBL] [Abstract][Full Text] [Related]
5. Immature myeloid cells in the tumor microenvironment: Implications for immunotherapy.
Kamran N; Chandran M; Lowenstein PR; Castro MG
Clin Immunol; 2018 Apr; 189():34-42. PubMed ID: 27777083
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function.
Gielen PR; Schulte BM; Kers-Rebel ED; Verrijp K; Bossman SA; Ter Laan M; Wesseling P; Adema GJ
Neuro Oncol; 2016 Sep; 18(9):1253-64. PubMed ID: 27006175
[TBL] [Abstract][Full Text] [Related]
7. Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression.
Alban TJ; Bayik D; Otvos B; Rabljenovic A; Leng L; Jia-Shiun L; Roversi G; Lauko A; Momin AA; Mohammadi AM; Peereboom DM; Ahluwalia MS; Matsuda K; Yun K; Bucala R; Vogelbaum MA; Lathia JD
Front Immunol; 2020; 11():1191. PubMed ID: 32625208
[TBL] [Abstract][Full Text] [Related]
8. Altered Metabolism in Glioblastoma: Myeloid-Derived Suppressor Cell (MDSC) Fitness and Tumor-Infiltrating Lymphocyte (TIL) Dysfunction.
Di Ianni N; Musio S; Pellegatta S
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33923299
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients.
Dubinski D; Wölfer J; Hasselblatt M; Schneider-Hohendorf T; Bogdahn U; Stummer W; Wiendl H; Grauer OM
Neuro Oncol; 2016 Jun; 18(6):807-18. PubMed ID: 26578623
[TBL] [Abstract][Full Text] [Related]
10. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
[TBL] [Abstract][Full Text] [Related]
11. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs.
Lakshmanachetty S; Cruz-Cruz J; Hoffmeyer E; Cole AP; Mitra SS
Cells; 2021 Apr; 10(4):. PubMed ID: 33919732
[TBL] [Abstract][Full Text] [Related]
12. Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells.
Peereboom DM; Alban TJ; Grabowski MM; Alvarado AG; Otvos B; Bayik D; Roversi G; McGraw M; Huang P; Mohammadi AM; Kornblum HI; Radivoyevitch T; Ahluwalia MS; Vogelbaum MA; Lathia JD
JCI Insight; 2019 Nov; 4(22):. PubMed ID: 31600167
[TBL] [Abstract][Full Text] [Related]
13. Myeloid-Derived Suppressive Cells Promote B cell-Mediated Immunosuppression via Transfer of PD-L1 in Glioblastoma.
Lee-Chang C; Rashidi A; Miska J; Zhang P; Pituch KC; Hou D; Xiao T; Fischietti M; Kang SJ; Appin CL; Horbinski C; Platanias LC; Lopez-Rosas A; Han Y; Balyasnikova IV; Lesniak MS
Cancer Immunol Res; 2019 Dec; 7(12):1928-1943. PubMed ID: 31530559
[TBL] [Abstract][Full Text] [Related]
14. Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner.
Bayik D; Zhou Y; Park C; Hong C; Vail D; Silver DJ; Lauko A; Roversi G; Watson DC; Lo A; Alban TJ; McGraw M; Sorensen M; Grabowski MM; Otvos B; Vogelbaum MA; Horbinski C; Kristensen BW; Khalil AM; Hwang TH; Ahluwalia MS; Cheng F; Lathia JD
Cancer Discov; 2020 Aug; 10(8):1210-1225. PubMed ID: 32300059
[TBL] [Abstract][Full Text] [Related]
15. Tumor cell and immune cell profiles in primary human glioblastoma: Impact on patient outcome.
González-Tablas Pimenta M; Otero Á; Arandia Guzman DA; Pascual-Argente D; Ruíz Martín L; Sousa-Casasnovas P; García-Martin A; Roa Montes de Oca JC; Villaseñor-Ledezma J; Torres Carretero L; Almeida M; Ortiz J; Nieto A; Orfao A; Tabernero MD
Brain Pathol; 2021 Mar; 31(2):365-380. PubMed ID: 33314398
[TBL] [Abstract][Full Text] [Related]
16. M-MDSCs mediated trans-BBB drug delivery for suppression of glioblastoma recurrence post-standard treatment.
Yu T; Wang K; Wang J; Liu Y; Meng T; Hu F; Yuan H
J Control Release; 2024 May; 369():199-214. PubMed ID: 38537717
[TBL] [Abstract][Full Text] [Related]
17. Immune consequences of penfluridol treatment associated with inhibition of glioblastoma tumor growth.
Ranjan A; Wright S; Srivastava SK
Oncotarget; 2017 Jul; 8(29):47632-47641. PubMed ID: 28512255
[TBL] [Abstract][Full Text] [Related]
18. The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment.
Chang N; Ahn SH; Kong DS; Lee HW; Nam DH
Mol Cell Endocrinol; 2017 Aug; 451():53-65. PubMed ID: 28089821
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Targeting Myeloid-Derived Suppressor Cells (MDSCs) in Tumor Microenvironment.
Gao X; Sui H; Zhao S; Gao X; Su Y; Qu P
Front Immunol; 2020; 11():585214. PubMed ID: 33613512
[TBL] [Abstract][Full Text] [Related]
20. Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions.
Zhang X; Ding K; Wang J; Li X; Zhao P
Biomed Pharmacother; 2019 Jan; 109():39-46. PubMed ID: 30391707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
